Insulet Appoints Ashley McEvoy as CEO, Succeeding Hollingshead

Dow Jones
28 Apr
 

By Connor Hart

 

Insulet named Ashley McEvoy as its chief executive, taking the reins from Jim Hollingshead.

McEvoy has nearly three decades of experience, the medical-devices company said Monday. She most recently served as executive vice president of Johnson & Johnson's MedTech business, and previously held various roles of increasing responsibility at the healthcare conglomerate.

She has served as a member of Procter & Gamble's board since 2023.

McEvoy, who will additionally serve as president and has joined Insulet's board, said the Action, Mass., company has untapped growth potential, adding that she hopes to enhance innovation and drive global expansion during her tenure.

She succeeds Hollingshead, who mutually agreed with the Insulet's board that it was the right time to transition leadership, the company said. He has entered a consulting arrangement with the company to facilitate a smooth transition.

With the disclosure of its new top officer, Insulet said it will reschedule its investor day conference, initially planned for June 5, to a later day.

It also expects to exceed its previously provided first-quarter revenue outlook and raise its full-year guidance. The company is scheduled to release its first-quarter earnings on May 8.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

April 28, 2025 06:26 ET (10:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10